Robenacoxib pharmacokinetics in sheep following oral, subcutaneous, and intravenous administration

August 17, 2022

Title

Robenacoxib pharmacokinetics in sheep following oral, subcutaneous, and intravenous administration

Author

Charbel Fadel, Beata Łebkowska-Wieruszewska, Irene Sartini, Andrzej Lisowski, Amnart Poapolathep, Mario Giorgi

Year

2022

Journal

Journal of Veterinary Pharmacology and Therapeutics

Abstract

The aim of this study was to evaluate the pharmacokinetics (PK) of robenacoxib (RX), a COX-2 selective non-steroidal anti-inflammatory drug, in sheep after single subcutaneous (SC), oral (PO), and intravenous (IV) administration. Five healthy female sheep underwent a three-phase parallel study design with a washout period of 4 weeks, in which sheep received a 4 mg/kg SC dose in phase 1, a 4 mg/kg PO administration in phase 2, and a 2 mg/kg IV administration in phase 3. Plasma RX concentrations were measured over a 48 h period for each treatment using HPLC coupled to a UV multiple wavelength detector, and the PK parameters were estimated using a non-compartmental method. Following IV administration, terminal elimination half-life, volume of distribution at steady state, and total clearance were 2.64 h, 0.077 L/kg, and 0.056 L/h kg, respectively. The mean peak plasma concentrations following SC and PO administrations were 7.04 and 3.01 μg/mL, respectively. The mean bioavailability following SC and PO administrations were 45.98% and 16.58%, respectively. The SC route may be proposed for use in sheep. However, the multi-dose and pharmacodynamic studies are necessary to establish more accurately its safety and efficacy in sheep.

Instrument

LC-2000,4000

Keywords

pharmacokinetics, robenacoxib,